公开(公告)号：US20250064064A1

公开(公告)日：2025-02-27

申请号：US18719164

申请日：2022-12-12

Applicant: Amgen Inc.

Inventor： Evan Kruchowy ,  Sai Chakradhar Padala ,  Daniel Marsiglio

IPC: A01N59/00 ,  A01P1/00 ,  A61L2/20 ,  A61L101/02

Abstract: A method for decontaminating a chamber interior using a VPHP decontamination cycle includes sealing the chamber interior, circulating a dose of gas in the chamber interior for a dwell time, and aerating the chamber interior until no more than an allowable remaining amount of the gas remains in the chamber interior. A method for selecting parameters for a VPHP decontamination cycle for a chamber interior includes performing a plurality of experiments testing different amounts of gas and different amounts of time, selecting a dose of the gas to be a least amount of gas that maintains full saturation of the chamber interior over a selected time, and selecting a dwell time such that the dwell time is both less than or equal to the selected time and a least amount of time for which, after circulating the dose of the gas, the remaining amount of viable spores is allowable.

公开(公告)号：US12156900B2

公开(公告)日：2024-12-03

申请号：US16764463

申请日：2018-11-16

Applicant: Amgen Inc.

Inventor： Yael Wexler-Cohen ,  William J. Callahan ,  Robert Matthew Fesinmeyer ,  Rahul Rajan Kaushik ,  Sai Chakradhar Padala

IPC: A61K38/18 ,  A61K9/00 ,  A61K47/02 ,  A61K47/14 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34

Abstract: Protein formulations and methods of making and using such formulations are provided herein. The formulation can be an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the formulation comprises a VEGFR-Fc fusion protein, such as aflibercept.